Opara Emmanuel C, McQuilling John P, Farney Alan C
Wake Forest Institute for Regenerative Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
Methods Mol Biol. 2013;1001:261-6. doi: 10.1007/978-1-62703-363-3_21.
Islet transplantation is the most exciting treatment option for individuals afflicted with Type 1 diabetes. However, the severe shortage of human pancreas and the need to use risky immunosuppressive drugs to prevent transplant rejection remain two major obstacles for the routine use of islet transplantation in diabetic patients. Successful development of a bioartificial pancreas using the approach of microencapsulation with perm-selective coating of islets with biopolymers for graft immunoisolation holds tremendous promise for diabetic patients because it has great potential to overcome these two barriers. In this chapter, we provide a detailed description of the microencapsulation process.
胰岛移植对于1型糖尿病患者来说是最令人兴奋的治疗选择。然而,人类胰腺的严重短缺以及使用有风险的免疫抑制药物来防止移植排斥反应的必要性,仍然是胰岛移植在糖尿病患者中常规应用的两大障碍。采用生物聚合物对胰岛进行选择性渗透涂层微囊化的方法成功开发生物人工胰腺,对糖尿病患者具有巨大的前景,因为它有很大的潜力克服这两个障碍。在本章中,我们将详细描述微囊化过程。